Hereditary Hypertension: Difference between revisions
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
HPT is controlled by complex, not well understood [[Genetics and Health|genetic]], and [[Epigenetics|epigenetic]] mechanisms, working through both heritable and environmental factors. The regulatory control mechanisms of HPT is regulated complicated molecular and pathophysiological systems, suggesting that genetic determinants and epigenetic factors control our gene regulation, expression, and function, which in turn influence our vulnerability to the development of HPT. | HPT is controlled by complex, not well understood [[Genetics and Health|genetic]], and [[Epigenetics|epigenetic]] mechanisms, working through both heritable and environmental factors. The regulatory control mechanisms of HPT is regulated complicated molecular and pathophysiological systems, suggesting that genetic determinants and epigenetic factors control our gene regulation, expression, and function, which in turn influence our vulnerability to the development of HPT. | ||
== | == Genetic Risk Score == | ||
HPT untreated increases the risk of major health complications for example coronary artery disease (CAD) and stroke. Twenty years ago the first genome-wide association study for hypertension was initiated and now over 1000 blood pressure (BP) loci have been found which explain ∼6% of the single nucleotide polymorphism-based heritability. These successes into HPT genes provide new pathological insights and possible drug discovery opportunities. Now a BP genetic risk score (GRSs), facilitating population disease risk stratification. A GRS can estimate the overall probability, or risk, a person has for developing an outcome of interest based on their genotypes. A leap forward in HPT research.<ref>Olczak KJ, Taylor‐Bateman V, Nicholls HL, Traylor M, Cabrera CP, Munroe PB. [https://onlinelibrary.wiley.com/doi/10.1111/joim.13352 Hypertension genetics past, present and future applications]. Journal of internal medicine. 2021 Dec;290(6):1130-52.Available: https://onlinelibrary.wiley.com/doi/10.1111/joim.13352 (accessed 7.5.2024)</ref> | |||
== Resources == | == Resources == | ||
Revision as of 08:43, 7 May 2024
Original Editor - Lucinda hampton
Top Contributors - Lucinda hampton
Introduction[edit | edit source]
Hypertension (HPT) is known to be a complex heterogeneous condition controlled by many genes. The factors that regulate HPT have a strong genetic component, but the precise genes involved in HTN development are not well known. The drug therapy available for HPT do not always prevent the occurrence of high BP.
- 18 genotype/phenotype groups have been found to be linked nearly 1/2 of the primary HPT populations, giving a pathway to discover treatment/prevention better individual primary HPT treatments.[1]
- Novel drug treatment approaches are needed that use this genetic approach and personalized medicine.[2]
Controlling Factors[edit | edit source]
HPT is controlled by complex, not well understood genetic, and epigenetic mechanisms, working through both heritable and environmental factors. The regulatory control mechanisms of HPT is regulated complicated molecular and pathophysiological systems, suggesting that genetic determinants and epigenetic factors control our gene regulation, expression, and function, which in turn influence our vulnerability to the development of HPT.
Genetic Risk Score[edit | edit source]
HPT untreated increases the risk of major health complications for example coronary artery disease (CAD) and stroke. Twenty years ago the first genome-wide association study for hypertension was initiated and now over 1000 blood pressure (BP) loci have been found which explain ∼6% of the single nucleotide polymorphism-based heritability. These successes into HPT genes provide new pathological insights and possible drug discovery opportunities. Now a BP genetic risk score (GRSs), facilitating population disease risk stratification. A GRS can estimate the overall probability, or risk, a person has for developing an outcome of interest based on their genotypes. A leap forward in HPT research.[3]
Resources[edit | edit source]
- bulleted list
- x
or
- numbered list
- x
References[edit | edit source]
- ↑ Manosroi W, Williams GH. Genetics of human primary hypertension: focus on hormonal mechanisms. Endocrine reviews. 2019 Jun;40(3):825-56.Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936319/ (7.5.2024)
- ↑ Pandey KN. Genetic and Epigenetic Mechanisms Regulating Blood Pressure and Kidney Dysfunction. Hypertension. 2024 Mar 28.Available:https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.124.22072 (accessed 7.5.2024)
- ↑ Olczak KJ, Taylor‐Bateman V, Nicholls HL, Traylor M, Cabrera CP, Munroe PB. Hypertension genetics past, present and future applications. Journal of internal medicine. 2021 Dec;290(6):1130-52.Available: https://onlinelibrary.wiley.com/doi/10.1111/joim.13352 (accessed 7.5.2024)
